Compare XLO & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | POM |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 47.1M |
| IPO Year | 2021 | N/A |
| Metric | XLO | POM |
|---|---|---|
| Price | $8.41 | $0.39 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | 31.3K | ★ 835.6K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,766,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $168.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 589.88 | N/A |
| 52 Week Low | $0.46 | $0.19 |
| 52 Week High | $9.25 | $6.43 |
| Indicator | XLO | POM |
|---|---|---|
| Relative Strength Index (RSI) | 69.92 | 60.59 |
| Support Level | $0.62 | $0.21 |
| Resistance Level | $9.22 | $0.43 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | -0.27 | 0.01 |
| Stochastic Oscillator | 29.47 | 77.52 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.